Spots Global Cancer Trial Database for TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TAS-116 Plus Palbociclib in Breast and Rb-null Cancer
Official Title: Phase Ib IIT of Heat Shock Protein 90 Inhibitor TAS-116 Combined With Cyclin-dependent Kinase 4/6 Inhibitor Palbociclib in Advanced Breast Cancer Progressing on Palbociclib & Treatment-refractory Solid Tumors With Retinoblastoma Deficiency
Study ID: NCT05655598
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of TAS-116 with palbociclib in two groups of patients: * Patients with advanced breast cancer that has become worse after taking palbociclib alone * Patients with cancers that have an abnormality in a gene called the "retinoblastoma gene".
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Lifespan Cancer Institute, Providence, Rhode Island, United States
Contact Details
Name: Wafik El-Deiry, MD, PhD, FACP
Affiliation: Brown University & Lifespan Cancer Institute
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
